Showing posts with label Public Health. Show all posts
Showing posts with label Public Health. Show all posts

Wednesday

US begins first human trial of coronavirus vaccine


The first human trial to evaluate a candidate vaccine against the new coronavirus has begun in Seattle, U.S. health officials said Monday, raising hopes in the global fight against the disease.

But it may be another year to 18 months before it becomes available, once it has passed more trial phases to prove it works and is safe.


The vaccine is called mRNA-1273 and was developed by U.S. National Institutes of Health (NIH) scientists and collaborators at biotechnology company Moderna, which is based in Cambridge, Massachusetts.

“The open-label trial will enroll 45 healthy adult volunteers ages 18 to 55 years over approximately 6 weeks,” the NIH said. “The first participant received the investigational vaccine today.”

Funding was also provided by the Oslo-based Coalition for Epidemic Preparedness Innovations (CEPI).

There are currently no approved vaccines or treatments against the coronavirus disease, known as COVID-19, which has infected more than 175,000 people across the world since it was first identified in central China in late December.

It has claimed 7,000 deaths, according to an AFP tally, most in China followed by Italy.

“Finding a safe and effective vaccine to prevent infection with SARS-CoV-2 is an urgent public health priority,” said Anthony Fauci, head of infectious diseases at the NIH, using the technical name for the virus that is believed to have originated in bats.

“This Phase 1 study, launched in record speed, is an important first step toward achieving that goal.”

The Seattle trial will study the impact of different doses delivered by intramuscular injection in the upper arm, with participants monitored for side-effects like soreness or fever.

Coronaviruses are spherical and have spikes protruding from their surface, giving them a crown-like appearance. The spike binds to human cells, allowing the virus to gain entry.


The Moderna candidate vaccine carries the genetic information of this spike in a substance called “messenger RNA.”

Injecting human tissue with the spike’s messenger RNA makes it grow inside the body, thereby eliciting an immune response without having actually infected a person with the full-blown virus.

Global race

Pharmaceuticals and research labs around the world are racing to develop both treatments and vaccines to the new coronavirus.

An antiviral treatment called remdesivir, made by U.S.-based Gilead Sciences, is already in the final stages of clinical trials in Asia and doctors in China have reported it has proven effective in fighting the disease.

But only randomized trials allow scientists to know for sure whether it really helps or whether patients would have recovered without it.

Another U.S. pharma called Inovio, which is creating a DNA-based vaccine, has said it will enter clinical trials next month.

Regeneron is trying to isolate coronavirus-fighting antibodies that can be administered intravenously to confer temporary immunity, and hopes to start human trials by summer.

According to the World Health Organization, 80% of COVID-19 cases are mild, 14% are severe and about 5% are critical, resulting in severe respiratory illness that causes the lungs to fill with fluid which in turn prevents oxygen from reaching organs.

Patients with mild cases recover in a week or two while severe cases can take six or more weeks.

Recent estimates suggest about 1% of all infected people die.

Agence France-Presse

Sunday

Dengue outbreak in Bangladesh: Hospitals struggling


DHAKA — Last Sunday, when Shahjadi Akter’s five-year-old daughter began running a fever, she rushed the child to Dhaka Medical College Hospital from her Hosni Dalan house. Doctors there diagnosed her with dengue, but could not admit her due to a lack of beds.

They told Shahjadi that since the infection was at an initial stage, it could be treated at home.

That, however, was not the case as the situation took a turn for the worse.

Five-year-old Alia’s condition deteriorated and she was rushed back to DMCH around 2:00am on Friday. Again, there were no beds available.

Left with little choice, Shahjadi spent the next five hours going to three different hospitals — Mitford Hospital, Icddrb, and Dhaka Shishu Hospital — with her daughter in tow. Unfortunately, she got the same response.

As a last-ditch effort, she took Alia to the Shaheed Suhrawardy Medical College Hospital (ShSMC) around 7:00am. Doctors there were initially reluctant to take her in, but seeing Alia’s blood pressure dropping fast, they finally admitted her.


“I could manage a place on the walkway of the hospital. Alia is doing better now,” Shahjadi told The Daily Star yesterday.

Alia’s predicament sums up the grim picture of how medical centers in the capital (Dhaka) are struggling to accommodate a growing number of dengue patients.

This year, hospitals have seen a record number of dengue patients, unmatched in the past 18 years.

A total of 10,528 people have been infected with the mosquito-borne disease till July 27. Last year, the total number was 10,148, according to the Directorate General of Health Services (DGHS).

The number of dengue patients exceeded the 10,000 mark only twice in the last 18 years: in 2018 and this year, according to a DGHS report. The previous highest was 6,232 in 2002.

Meanwhile, authorities of different hospitals in the capital said at least 30 dengue patients have died so far. But the DGHS maintains that only eight have died of the disease.

Explaining the disparity in the number of deaths, Prof Dr Meerjady Sa-brina Flora, director of Institute of Epidemiology, Disease Control and Research (IEDCR) and also the head of death review committee of the government, said after a patient dies, they collect information, as well as blood samples, of the deceased to confirm the cause of the death. Only after getting all those, they can declare whether it was dengue-related or not.

Director of Shishu Hospital Prof Syed Shafi Ahmed said 87 children were taking treatment in the hospital, and they were given free dengue tests and treatment to 25 to 40 patients every day at the outdoor.

Around 400 patients have so far taken dengue treatment at the 664-bed hospital since March.

“Round the year we have a shortage of seats due to the large number of patients, but even then we have kept 87 seats in the hospital for dengue patients,” he said.

Shafi said they did not allow patients to stay on the floor as it was difficult to manage.

HM Nazmul Ahsan, associate professor at ShSMC, said that considering the present dengue situation, they do not refuse any dengue patients despite having a capacity to handle only 60 patients.

Many patients are taking treatment at the hospital’s veranda and walkways, he said.

In DMCH, of the 800 beds in its medicine wards, 561 were occupied by dengue patients yesterday morning. The number was around 200 last week. At least 233 dengue patients were admitted to the hospital yesterday.

Dengue-related deaths

In Narayanganj, a man died of dengue on July 11 in the city’s Isdair.

His father Kaykobad Siddiqui said his son Sawon Kabir Salehin, 38, was diagnosed with dengue on July 11 and died in Islamia Heart Centre in Narayanganj.

Elsewhere, a first year student of Jahangirnagar University died of dengue yesterday, while she was on her way to Chattogram Medical College from Cox’s Bazar.

The victim U Khein Nu, a first year student of Pharmacy department, hailed from Cox’s Bazar.

Dengue outside capital

According to the DGHS, 373 people have been infected with dengue outside the capital since January.

Of them, 72 are in Dhaka division, 142 in Chattogram division, 71 in Khulna division, 40 in Rajshahi division, 35 in Barishal division and 13 in Sylhet division.

Most of the hospitals outside Dhaka, however, are struggling to diagnose dengue patients due to a lack of NS1 kits, which are used to do the diagnosis at the initial stage.

Saiful Ferdous, deputy director of Rajshahi Medical College Hospital, said they did not have the kits, but they were using the old method to diagnose patients.

Akhterul Islam, deputy director of Chattogram Medical College Hospital, said other than the blood separation machine, the hospital did not have any facility for dengue diagnosis.


“We can provide treatment to patients already diagnosed with dengue, but cannot diagnose a new patient. The tests have to be done elsewhere,” he said.

Bandarban civil surgeon Aung Shwe Prue Marma said no dengue pa-tient was detected in the district so far. Besides, the district had no laboratory for diagnosing the virus, he added.

Talking about the doctors dealing with dengue patients outside the capital, DGHS officials said the physicians did not have the NS1 kit to diagnose dengue instantly.

IEDCR’s Flora said they were yet to provide dengue diagnosing kits as the number of cases outside Dhaka was still comparatively very low.

The NS1 antigen test (nonstructural protein 1), is a test for dengue, introduced in 2006, which allows for rapid detection of the disease on the first day of fever, as antibodies appear some five or more days later.

DSCC fines building-owners for spreading infection 

Dhaka South City Corporation (DSCC) yesterday fined eight owners of under-construction buildings Tk 2.70 lakh as they found Aedes mosquito larva at the structures.

The mobile court visited 78 under construction buildings and found Aedes mosquito larva in eight of them.

Executive Magistrate of DSCC Mizanur Rahman said they fined them under section 269 of the penal code-1860, which has a provision for awarding six months’ imprisonment and fine or both for anyone who “unlawfully or negligently does any act which is likely to spread the infection of any disease dangerous to life.”

Dengue guidelines issued

The government yesterday issued a statement to raise awareness of the steps needed to stop the spread of dengue and the measures to protect themselves from being infected by the mosquito-borne disease.

Dengue peaks in the monsoon (April-October) season. Be alert during this period, a press release issued by the Press Information Department (PID) said.

It further said, “The carrier of the dengue fever, Aedes mosquito, breeds in clear water”, adding that one must not let water accumulate around their office, house or in neighboring areas. It suggested changing accumulated water in containers every three days.

“Aedes mosquito usually bites during the day. Cover your body, as much as possible, with your clothing to protect yourself from possible mosquito bites,” the release added.

“Use mosquito nets even while sleeping in the day time,” it advised.

Dengue-affected persons have been advised to identify it by not only the symptoms of fever, headache, muscular pain or red skin rash, as lately it has been observed that there are some exceptions, the release noted.

It advised dengue patients from taking any other medicine except paracetamol. The patient should be given plenty of fluids, it said, requesting a dengue test at the first sign of a fever.

It cautioned patients that even after remission of fever, one can have severe complications due to dengue.

Information ministry media cell

The information ministry introduced a media cell to provide necessary information to make people aware of the necessary guidelines about dengue treatment through both print and electronic media.

It would also give out information regarding flood, relief and shelter and spread awareness over the recent child kidnapping rumors.

source: newsinfo.inquirer.net

Thursday

State of emergency declared in California gas leak


The governor of California on Wednesday declared a state of emergency in a Los Angeles community where a massive gas leak has forced thousands of nearby residents from their homes.

In issuing the emergency order, Governor Jerry Brown said all state agencies would be mobilized to stop the leak that started in October in the Los Angeles suburb of Porter Ranch, to protect public health, and to help the local community.

"All state agencies will utilize state personnel, equipment, and facilities to ensure a continuous and thorough state response to this incident," Brown said in a statement.

He said his office would closely monitor the situation and provide timely updates to residents of the gated community located some 30 miles (48 kilometers) northwest of downtown Los Angeles.

Brown said he had met on Monday with Porter Ranch residents, thousands of whom have been relocated to temporary housing by the local gas company after complaining of headaches, nausea and nose bleeds.

Kristine Lloyd, a spokeswoman for the Southern California Gas Company (SoCalGas), said everything possible was being done to fix the leak, which officials have estimated was spewing out between 30,000 and 58,000 kilograms (66,000 and 127,000 pounds) of methane into the air per hour.

"Our focus remains on quickly and safely stopping the leak and minimizing the impact to our neighbors in Porter Ranch," she said in a statement.

"SoCalGas reaffirms our prior commitment to mitigate the environmental impact of the actual amount of natural gas released from the leak."

Officials have said that while the methane leaking from the Aliso Canyon facility poses no immediate danger to human health, its impact on the environment is significant as it is a potent greenhouse gas.

The California Air Resources Board estimates that the leak is so massive that at its peak at the end of November, it increased the West Coast state's greenhouse gas output from methane by as much as 25 percent.

"We really won't be able to assess the impact until the leak is sealed and we have data for the whole incident," said David Clegern, a spokesman for the governmental agency.

"But this is a lot of greenhouse gas for a single incident and it will need to be mitigated."

The leak was detected on October 23 in a well at more than 8,000 feet underground and SoCal Gas estimates it may take until the end of March for the repairs to be completed. — Agence France-Presse

source: gmanetwork.com

Sunday

India court blocks Bayer generic drug appeal


New Delhi, India - An Indian court has rejected German drug giant Bayer's bid to block a generic version of its blockbuster cancer treatment Nexavar by a local drug maker, a move hailed by activists on Saturday.

The judges rejected an appeal by Bayer on Friday that contested a March 2012 decision by India's patent controller, who had argued the price charged by Bayer for the liver and kidney drug -- $5,500-per-person, per month in India -- was far too costly for most Indians.

Medicins San Frontieres (MSF) on Saturday hailed the ruling, calling it a boost for public health.

The court's decision "demonstrates the independence of the Indian judiciary" in upholding the nation's right to legislate "with public health interests in mind", said Leena Menghaney, South Asia regional head of the medical charity's access campaign.

The court judgment highlighted India's "critical role" in "balancing intellectual property and public health", she said, adding it was clear to the court Bayer had recouped its drug research and development costs in just one year.

The Indian government gave local pharmaceutical house Natco Pharma a license to produce a copy of life-extending Nexavar at a 97-percent discount to the original price of the Bayer medicine in India.

"We are analyzing the (court) order and will determine any future course of action afterwards," Bayer said in a statement, adding the ruling "disappointed" the company.

The ruling could stoke tensions further with Western-based big pharmaceutical companies who say India flouts international patent protection law.

India says it is fully compliant with World Trade Organization patent rules. But the United States has already put India on a "watchlist" of intellectual property violators.

Since India's new right-wing government came to power in May, New Delhi has been under heavy pressure from Washington, prodded by the powerful US pharmaceutical industry, to dilute its strict patent laws.

Indian law stipulates drugs must "satisfy the test of novelty or inventiveness" to win patent protection and does not allow minor tweaks, called "evergreening," to prolong patent life.

Western companies say India's powerhouse generics industry and stringent patent filtering reduce commercial incentives to produce cutting-edge medicines.

India'a Lawyers' Collective, another rights group, said  the "momentous" judgment held wide-ranging implications for access to other medicines.

India's vast generics industry is a major supplier of cheap copycat, life-saving drugs to treat diabetes, cancer and other diseases afflicting people locally and globally who cannot afford expensive branded versions.

But health economists say it doesn't matter how far drug prices drop in India for some of the 1.25-billion population, as they are too desperately poor to afford them. India is home to one-third of the world's poorest, according to the World Bank. — Agence France-Presse


source: gmanetwork.com

Thursday

UN agency calls outdoor air pollution leading cause of cancer


LONDON - The air we breathe is laced with cancer-causing substances and should now be classified as carcinogenic to humans, the World Health Organization's (WHO) cancer agency said on Thursday.

The International Agency for Research on Cancer (IARC) cited data indicating that in 2010, 223,000 deaths from lung cancer worldwide resulted from air pollution, and said there was also convincing evidence it increases the risk of bladder cancer.

The WHO is a Geneva-based agency of the United Nations focused on international public health matters.

Air pollution, mostly caused by transport, power generation, industrial or agricultural emissions and residential heating and cooking, is already known to raise risks for a wide range of illnesses including respiratory and heart diseases.

Research suggests that in recent years, exposure levels have risen significantly in some parts of the world, particularly countries with large populations going through rapid industrialisation such as China.

"We now know that outdoor air pollution is not only a major risk to health in general, but also a leading environmental cause of cancer deaths," said Kurt Straif, head of the IARC's monographs section, which is tasked with ranking carcinogens.

"The air we breathe has become polluted with a mixture of cancer-causing substances."

In a statement released after a week-long meeting of experts reviewing the latest scientific literature, IARC said both outdoor air pollution and "particulate matter"—a major component of it—would now be classified among its Group 1 human carcinogens.

That ranks them alongside more than 100 other known cancer-causing substances in IARC's Group 1, including asbestos, plutonium, silica dust, ultraviolet radiation and tobacco smoke.

IARC's monographs program, sometimes known as the "encyclopedia of carcinogens," aims to be an authoritative source of scientific evidence on cancer-causing substances.

It has already classified many chemicals and mixtures that can be components of air pollution, including diesel engine exhaust, solvents, metals and dusts. But this is the first time that experts have classified outdoor air pollution as a cause of cancer.

"Our task was to evaluate the air everyone breathes rather than focus on specific air pollutants," said Dana Loomis, deputy head of the section. "The results from the reviewed studies point in the same direction: the risk of developing lung cancer is significantly increased in people exposed to air pollution."

Although both the composition and levels of air pollution can vary dramatically from one location to the next, IARC said its conclusions applied to all regions of the world.

IARC's director, Christopher Wild, said the agency's decision to classify outdoor air pollution as carcinogenic to humans was an important step towards alerting governments to its dangers and potential costs.

"There are effective ways to reduce air pollution and, given the scale of the exposure affecting people worldwide, this report should send a strong signal to the international community to take action," he said. — Reuters

source: gmanetwork.com